Lorlatinib, another ALK inhibitor that also inhibits ROS1 (a receptor tyrosine kinase), was approved in 2021 by the FDA for metastatic ALK-positive non-small cell lung cancer. This evidence concerns the gene ALK and non-small cell lung carcinoma.